Chagas disease: from Latin America to the world

References

• Gascon J, Bern C, Pinazo MJ. Chagas disease in Spain, the United States and other non-endemic countries. Acta Trop. 2010;115:22–27.
   PubMed Web of Science ®Google Scholar
• Hotez PJ, Molyneux DH, Fenwick A, et al. Control of neglected tropical diseases. N Engl J Med. 2007;357:1018–1027.
   PubMed Web of Science ®Google Scholar
• Lee BY, Bacon KM, Bottazzi ME, Hotez PJ. Global economic burden of Chagas disease: a computational simulation model. Lancet Infect Dis. 2013;1:342–348.
   Google Scholar
• Noireau F, Diosque P, Jansen AM. Trypanosoma cruzi: adaptation to its vectors and its hosts. Vet Res. 2009;40,26.
   Web of Science ®Google Scholar
• Gurtler RE, Cecere MC, Lauricella MA, Cardinal MV, Kitron U, Cohen JE. Domestic dogs and cats as sources of Trypanosoma cruzi infection in rural northwestern Argentina. Parasitology. 2007;134:69–82.
   PubMed Web of Science ®Google Scholar
• Zingales B, Andrade SG, Briones MR, et al. A new consensus for Trypanosoma cruzi intraspecific nomenclature: second revision meeting recommends TcI to TcVI. Mem Inst Oswaldo Cruz. 2009;104:1051–1054.
   PubMed Web of Science ®Google Scholar
• Tomlinson S, Raper J. Natural human immunity to trypanosomes. Parasitol Today. 1998;14:354–359.
   Google Scholar
• Truyens C, Carlier Y. Protective host response to parasite and its limitations. In: Telleria J, Tibayrenc M, editors. American Trypanosomiais. Chagas Disease. One Hundred Years of Research. London, UK: Elsevier; 2010:601–642.
   Google Scholar
• Andrade ZA. Patologia da Doença de Chagas. In: Brener Z, Andrade ZA, Barral-Netto M, editors. Trypanosoma Cruzi e Doença de Chagas. Rio de Janeiro, Brazil: Guanabara Koogan S/A; 2010:201–230.
   Google Scholar
• Almeida IC, Camargo MM, Procopio DO, et al. Highly purified glycosylphosphatidylinositols from Trypanosoma cruzi are potent proinflammatory agents. EMBO J. 2000;19:1476–1485.
   PubMed Web of Science ®Google Scholar
• Koberle F. Chagas’ disease and Chagas’ syndromes: the pathology of American trypanosomiasis. Adv Parasitol. 1968;6:63–116.
   PubMedGoogle Scholar
• Lázzari JO.. Autonomic nervous system alterations in Chagas’ disease: review of the litterature. In: Pan American Health Organization, editors. Chagas’ Disease and the Nervous System. Washington, DC: PAHO; 1994.
   Google Scholar
• Vitelli-Avelar DM, Sathler-Avelar R, Dias, JC, et al. Chagasic patients with indeterminate clinical form of the disease have high frequencies of circulating CD3+CD16-CD56+ natural killer T cells and CD4+CD25high regulatory T lymphocytes. Scand J Immunol. 2005;62:297–308.
   Web of Science ®Google Scholar
• Kierszenbaum F. Chagas’ disease and the autoimmunity hypothesis. Clin Microbiol Rev. 1999;12:210–223.
   PubMed Web of Science ®Google Scholar
• Cunha-Neto E, Teixeira PC, Nogueira LG, Kalil J. Autoimmunity. Adv Parasitol. 2011;76:129–152.
   PubMed Web of Science ®Google Scholar
• Kierszenbaum F. Where do we stand on the autoimmunity hypothesis of Chagas disease? Trends Parasitol. 2005;21:513–516.
   PubMed Web of Science ®Google Scholar
• Viotti R, Alarcon de Noya B, Araujo-Jorge T, et al. Towards a paradigm shift in the treatment of chronic Chagas disease. Antimicrob Agents Chemother. 2014;58(2):635–639.
   PubMed Web of Science ®Google Scholar
• Vitelli-Avelar DM, Sathler-Avelar R, Massara RL, et al. Are increased frequency of macrophage-like and natural killer (NK) cells, together with high levels of NKT and CD4+CD25high T cells balancing activated CD8+ T cells, the key to control Chagas’ disease morbidity? Clin Exp Immunol. 2006;145:81–92.
   PubMed Web of Science ®Google Scholar
• Rassi A Jr, Rassi A, Marin-Neto JA. Chagas disease. Lancet. 2010;375:1388–1402.
   PubMed Web of Science ®Google Scholar
• Carod-Artal FJ, Gascon J. Chagas disease and stroke. Lancet Neurol. 2010;9(5):533–542.
   PubMed Web of Science ®Google Scholar
• Guhl F, Jaramillo C, Vallejo GA, et al. Isolation of Trypanosoma cruzi DNA in 4,000-year-old mummified human tissue from northern Chile. Am J Phys Anthropol. 1999;108:401–407.
   PubMed Web of Science ®Google Scholar
• Bern C, Montgomery SP. An estimate of the burden of Chagas disease in the United States. Clin Infect Dis. 2009;49:e52–e54.
   PubMed Web of Science ®Google Scholar
• Medrano-Mercado N, Ugarte-Fernandez R, Butron V, et al. Urban transmission of Chagas disease in Cochabamba, Bolivia. Mem Inst Oswaldo Cruz. 2008;103:423–430.
   PubMed Web of Science ®Google Scholar
• Guhl F, Pinto N, Aguilera G. Sylvatic triatominae: a new challenge in vector control transmission. Mem Inst Oswaldo Cruz. 2009;104(1):71–75.
   Google Scholar
• Moncayo A, Silveira AC. Current epidemiological trends for Chagas disease in Latin America and future challenges in epidemiology, surveillance and health policy. Mem Inst Oswaldo Cruz. 2009;104(1):17–30.
   Google Scholar
• Schmunis GA. Epidemiology of Chagas disease in non-endemic countries: the role of international migration. Mem Inst Oswaldo Cruz. 2007;102(1):75–85.
   Google Scholar
• Jackson Y, Varcher Herrera M, Gascon J. Economic crisis and increased immigrant mobility: new challenges in managing Chagas disease in Europe. Bull World Health Organ. 2014;92(10):771–772.
   Web of Science ®Google Scholar
• Pan American Health Organization (PAHO). Estimación cuantitativa de la enfermedad de Chagas en las Americas. Montevideo, Uruguay: PAHO; 2006.
   Google Scholar
• Basile L, Jansa JM, Carlier Y, et al. Chagas disease in European countries: the challenge of a surveillance system. Euro Surveill. 2011;16(37). pii: 19968.
   Google Scholar
• Guerri-Guttenberg RA, Grana DR, Ambrosio G, Milei J. Chagas cardiomyopathy: Europe is not spared! Eur Heart J. 2008;29:2587–2591.
   PubMed Web of Science ®Google Scholar
• da Silva Valente SA, de Costa Valente V, Neto HF. Considerations on the epidemiology and transmission of Chagas disease in the Brazilian Amazon. Mem Inst Oswaldo Cruz. 1999;94(1):395–398.
   Google Scholar
• Dias JCP. Epidemiologia. In: Brener Z, Andrade ZA, Barral-Netto M, editors. Trypanosoma Cruzi e Doença de Chagas. Rio de Janeiro, Brazil: Guanabara Koogan S/A; 2000:48–74.
   Google Scholar
• Schmunis GA. A Tripanossomíase Americana e seu Impacto na Saúde Pública das America. In: Brener Z, Andrade ZA, Barral-Netto M, editors. Trypanosoma Cruzi e Doença de Chagas. Rio de Janeiro, Brazil: Guanabara Koogan S/A; 2000:1–15.
   Google Scholar
• Carlier Y, Torrico F. Congenital infection with Trypanosoma cruzi: from mechanisms of transmission to strategies for diagnosis and control. Rev Soc Bras Med Trop. 2003;36:767–771.
   PubMedGoogle Scholar
• Fernandez-Aguilar S, Lambot MA, Torrico F, et al. Placental lesions in human Trypanosoma cruzi infection. Rev Soc Bras Med Trop. 2005;38(2):84–86.
   Google Scholar
• World Health Organization (WHO). Control of Chagas’ Disease. Geneva, Switzerland: WHO; 2002:1–109.
   Google Scholar
• Luquetti AO, Rassi A. Diagnóstico laboratorial da infeccao pelo Trypanosoma cruzi. In: Brener Z, Andrade ZA, Barral-Netto M, editors. Trypanosoma Cruzi e Doença de Chagas. Rio de Janeiro, Brazil: Guanabara Koogan S/A; 2000:344–378.
   Google Scholar
• Gomes YM, Lorena VM, Luquetti AO. Diagnosis of Chagas disease: what has been achieved? What remains to be done with regard to diagnosis and follow up studies? Mem Inst Oswaldo Cruz. 2009;104(1):115–121.
   Google Scholar
• Brasil PE, De Castro L, Hasslocher-Moreno AM, et al. ELISA versus PCR for diagnosis of chronic Chagas disease: systematic review and meta-analysis. BMC Infect Dis. 2010;25;10:337.
   Web of Science ®Google Scholar
• Schijman AG, Bisio M, Orellana L, et al. International study to evaluate PCR methods for detection of Trypanosoma cruzi DNA in blood samples from Chagas disease patients. PLoS Negl Trop Dis. 2011;5:e931.
   PubMed Web of Science ®Google Scholar
• Murcia L, Carrilero B, Muñoz MJ, Iborra MA, Segovia M. Usefulness of PCR for monitoring benznidazole response in patients with chronic Chagas’ disease: a prospective study in a non-disease-endemic country. J Antimicrob Chemother. 2010;65(8):1759–1764.
   PubMed Web of Science ®Google Scholar
• Pinazo MJ, Miranda B, Rodríguez-Villar C, et al. Recommendations for management of Chagas disease in organ and hematopoietic tissue transplantation programs in nonendemic areas. Transplant Rev. 2011;25(3):91–101.
   Web of Science ®Google Scholar
• Burgos JM, Altcheh J, Petrucelli N, et al. Molecular diagnosis and treatment monitoring of congenital transmission of Trypanosoma cruzi to twins of a triplet delivery. Diagn Microbiol Infect Dis. 2009;65(1):58–61.
   Web of Science ®Google Scholar
• Prata A. Clinical and epidemiological aspects of Chagas disease. Lancet Infect Dis. 2001;1:92–100.
   PubMedGoogle Scholar
• Bern C, Montgomery SP, Herwaldt BL, et al. Evaluation and treatment of chagas disease in the United States: a systematic review. JAMA. 2007;298:2171–2181.
   PubMed Web of Science ®Google Scholar
• Schijman AG, Altcheh J, Burgos JM, et al. Aetiological treatment of congenital Chagas’ disease diagnosed and monitored by the polymerase chain reaction. J Antimicrob Chemother. 2003;52:441–449.
   PubMed Web of Science ®Google Scholar
• Sosa Estani S, Segura EL, Ruiz AM, Velazquez E, Porcel BM, Yampotis C. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas’ disease. Am J Trop Med Hyg. 1998;59:526–529.
   PubMed Web of Science ®Google Scholar
• Viotti R, Vigliano C, Lococo B, et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann Intern Med. 2006;144:724–734.
   PubMed Web of Science ®Google Scholar
• Marin-Neto JA, Rassi A Jr, Avezum A Jr, et al; BENEFIT Investigators. The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease. Mem Inst Oswaldo Cruz. 2009;104(Suppl 1):319–324.
   PubMedGoogle Scholar
• Fabbro DL, Danesi E, Olivera V, et al. Trypanocide treatment of women infected with Trypanosoma cruzi and its effect on preventing congenital Chagas. PLoS Negl Trop Dis. 2014;8(11):e3312.
   PubMed Web of Science ®Google Scholar
• Pinazo MJ, Munoz J, Posada E, et al. Tolerance of benznidazole in treatment of Chagas’ disease in adults. Antimicrob Agents Chemother. 2010;54:4896–4899.
   PubMed Web of Science ®Google Scholar
• Sosa-Estani S, Segura EL. Etiological treatment in patients infected by Trypanosoma cruzi: experiences in Argentina. Curr Opin Infect Dis. 2006;19:583–587.
   PubMed Web of Science ®Google Scholar
• Jackson Y, Alirol E, Getaz L, Wolff H, Combescure C, Chappuis F. Tolerance and safety of nifurtimox in patients with chronic Chagas disease. Clin Infect Dis. 2010;51(10):e69–e75.
   PubMed Web of Science ®Google Scholar
• Buckner FS. Sterol 14-demethylase inhibitors for Trypanosoma cruzi infections. Adv Exp Med Biol. 2008;625:61–80.
   Web of Science ®Google Scholar
• Molina I, Gómez i Prat J, Salvador F, et al. Randomized trial of posaconazole and benznidazole for chronic Chagas’ disease. N Engl J Med. 2014;370(20):1899–1908.
   PubMed Web of Science ®Google Scholar
• Torrico F.. E1224 results of proof of concept clinical trial in patients with chronic Chagas disease. In: Proceedings of 62nd Annual Meeting of American society of Tropical Medicine and Hygiene; November 13–17, 2013; Washington, DC.
   Google Scholar
• Pereira IR, Vilar-Pereira G, Marques V, et al. A human type 5 adenovirus- based Trypanosoma cruzi therapeutic vaccine re-programs immune response and reverses chronic cardiomyopathy. PLoS Pathog. 2015;24; 11(1):e1004594.
   Google Scholar
• Fabbro DL, Streiger ML, Arias ED, Bizai ML, del Barco M, Amicone NA. Trypanocide treatment among adults with chronic Chagas disease living in Santa Fe city (Argentina), over a mean follow-up of 21 years: parasitological, serological and clinical evolution. Rev Soc Bras Med Trop. 2007;40:1–10.
   PubMed Web of Science ®Google Scholar
• Bahia MT, de Andrade IM, Martins TA, et al. Fexinidazole: a potential new drug candidate for Chagas disease. PLoS Negl Trop Dis. 2012;6(11):e1870.
   PubMed Web of Science ®Google Scholar
• Pinazo MJ, Espinosa G, Gallego M, Lopez-Chejade PL, Urbina JA, Gascon J. Successful treatment with posaconazole of a patient with chronic Chagas disease and systemic lupus erythematosus. Am J Trop Med Hyg. 2010;82:583–587.
   PubMed Web of Science ®Google Scholar
• Urbina JA. New advances in the management of a long-neglected disease. Clin Infect Dis. 2009;49:1685–1687.
   PubMed Web of Science ®Google Scholar
• Garcia-Alvarez A, Sitges M, Pinazo MJ, et al. Chagas cardiomyopathy: the potential of diastolic dysfunction and brain natriuretic peptide in the early identification of cardiac damage. PLoS Negl Trop Dis. 2010; 4(9). pii: e826.
   PubMed Web of Science ®Google Scholar
• Saravia SG, Haberland A, Bartel S, et al. Cardiac troponin T measured with a highly sensitive assay for diagnosis and monitoring of heart injury in chronic Chagas disease. Arch Pathol Lab Med. 2011;135:243–248.
   PubMed Web of Science ®Google Scholar
• Mello RP, Szarf G, Schvartzman PR, et al. Delayed enhancement cardiac magnetic resonance imaging can identify the risk for ventricular tachycardia in chronic Chagas’ heart disease. Arq Bras Cardiol. 2012;98:421–430.
   PubMed Web of Science ®Google Scholar
• Regueiro A, Garcia-Alvarez A, Sitges M, et al. Myocardial involvement in Chagas disease: Insights from cardiac magnetic resonance. Int J Cardiol. 2011;165:107–112.
   Web of Science ®Google Scholar
• Perez-Ayala A, Perez-Molina JA, Norman F, Monge-Maillo B, Faro MV, Lopez-Velez R. Gastro-intestinal Chagas disease in migrants to Spain: prevalence and methods for early diagnosis. Ann Trop Med Parasitol. 2011;105:25–29.
   PubMed Web of Science ®Google Scholar
• Silva LC, Vicentine FP, Herbella FA. High resolution manometric findings in patients with Chagas’ disease esophagopathy. Asian Pac J Trop Med. 2012;5:110–112.
   Web of Science ®Google Scholar
• Pinazo MJ, Lacima G, Elizalde JI, et al. Characterization of digestive involvement in patients with chronic T. cruzi infection in Barcelona, Spain. PLoS Negl Trop Dis. 2014;8(8):e3105.
   Web of Science ®Google Scholar
• Gascón J, Albajar P, Cañas E, et al. [Diagnosis, management and treatment of chronic Chagas’ heart disease in areas where Trypanosoma cruzi infection is not endemic]. Rev Esp Cardiol. 2007;60(3):285–293. Published in Spanish and English.
   Web of Science ®Google Scholar
• Pinazo MJ, Cañas E, Elizalde JI, et al. Diagnosis, management and treatment of chronic Chagas’ gastrointestinal disease in areas where Trypanosoma cruzi infection is not endemic. Gastroenterol Hepatol. 2010;33(3):191–200.
   Web of Science ®Google Scholar
• Pérez-Molina JA, Rodríguez-Guardado A, Soriano A, et al. Guidelines on the treatment of chronic coinfection by Trypanosoma cruzi and HIV outside endemic areas. HIV Clin Trials. 2011;12(6):287–298.
   PubMed Web of Science ®Google Scholar
• Guhl F, Vallejo GA. Interruption of Chagas disease transmission in the Andean countries: Colombia. Mem Inst Oswaldo Cruz. 1999;94(1):413–415.
   Google Scholar
• Klotz SA, Dorn PL, Mosbacher M, Schmidt JO. Kissing bugs in the United States: risk for vector-borne disease in humans. Envion Health Insights. 2014;8(Suppl 2):49–59.
   Google Scholar
• Cantey PT, Stramer SL, Townsend RL, et al. The United States Trypanosoma cruzi Infection Study: evidence for vector-borne transmission of the parasite that causes Chagas disease among United States blood donors. Transfusion. 2012;52:1922–1930.
   PubMed Web of Science ®Google Scholar
• Alarcon de Noya B, Diaz-Bello Z, Colmenares C, et al. Large urban outbreak of orally acquired acute Chagas disease at a school in Caracas, Venezuela. J Infect Dis. 2010;201:1308–1315.
   PubMed Web of Science ®Google Scholar
• Coura JR, Dias JC. Epidemiology, control and surveillance of Chagas disease: 100 years after its discovery. Mem Inst Oswaldo Cruz. 2009;104(1):31–40.
   Google Scholar
• Shikanai-Yasuda MA, Marcondes CB, Guedes LA, et al. Possible oral transmission of acute Chagas’ disease in Brazil. Rev Inst Med Trop Sao Paulo. 1991;33:351–357.
   PubMed Web of Science ®Google Scholar
• Alonso-Vega C, Billot C, Torrico F. Achievements and challenges upon the implementation of a program for national control of congenital Chagas in Bolivia: results 2004–2009. PLoS Negl Trop Dis. 2013;7:e2304.
   PubMed Web of Science ®Google Scholar
• Luquetti AO, Dias JC, Prata A. Diagnosis and treatment of congenital infection caused by Trypanosoma cruzi in Brazil. Rev Soc Bras Med Trop. 2005;38(Suppl 2):27–28.
   Google Scholar
• Sosa-Estani S. Congenital transmission of Trypanosoma cruzi infection in Argentina. Rev Soc Bras Med Trop. 2005;38(Suppl 2):29–32.
   Google Scholar
• Pan American Health Organization (PAHO). Consultation on Congenital Chagas Disease, Its Epidemiology and Management [OPS/DPC/CD/301/04]. Washington, DC: PAHO; 2004.
   Google Scholar
• Munoz J, Coll O, Juncosa T, et al. Prevalence and vertical transmission of Trypanosoma cruzi infection among pregnant Latin American women attending 2 maternity clinics in Barcelona, Spain. Clin Infect Dis. 2009;48:1736–1740.
   PubMed Web of Science ®Google Scholar
• Requena-Méndez A, López MC, Angheben A, et al. Evaluating Chagas disease progression and cure through blood-derived biomarkers: a systematic review. Expert Rev Anti Infect Ther. 2013;11(9):957–976.
   PubMed Web of Science ®Google Scholar
• Sicuri E, Munoz J, Pinazo MJ, et al. Economic evaluation of Chagas disease screening of pregnant Latin American women and of their infants in a non endemic area. Acta Trop. 2011;118:110–117.
   PubMed Web of Science ®Google Scholar
• Huprikar S, Bosserman E, Patel G, et al. Donor-derived Trypanosoma cruzi infection in solid organ recipients in the United States, 2001–2011. Am J Transplant. 2013(9):2418–2425.
   Google Scholar
• Jackson Y, Dang T, Schnetzler B, Pascual M, Meylan P. Trypanosoma cruzi fatal reactivation in a heart transplant recipient in Switzerland. J Heart Lung Transplant. 2011;30(4):484–485.
   Web of Science ®Google Scholar
• Piron M, Verges M, Munoz J, et al. Seroprevalence of Trypanosoma cruzi infection in at-risk blood donors in Catalonia (Spain). Transfusion. 2008;48:1862–1868.
   PubMed Web of Science ®Google Scholar
• Frank M, Hegenscheid B, Janitschke K, Weinke T. Prevalence and epidemiological significance of Trypanosoma cruzi infection among Latin American immigrants in Berlin, Germany. Infection. 1997;25:355–358.
   Web of Science ®Google Scholar
• Kirchhoff LV, Gam AA, Gilliam FC. American trypanosomiasis (Chagas’ disease) in Central American immigrants. Am J Med. 1987;82:915–920.
   Web of Science ®Google Scholar
• Steele LS, MacPherson DW, Kim J, Keystone JS, Gushulak BD. The sero-prevalence of antibodies to Trypanosoma cruzi in Latin American refugees and immigrants to Canada. J Immigr Minor Health. 2007;9:43–47.
   Google Scholar
• Gascon J, Vilasanjuan R, Lucas A. The need for global collaboration to tackle hidden public health crisis of Chagas disease. Expert Rev Anti Infect Ther. 2004;12(4):393–395.
   Google Scholar
• Tarleton R, Gürtler RE, Urbina J, Ramsey J, Viotti R. Chagas disease and the London declaration on neglected tropical diseases. Plos Negl Trop Dis. 2014;8(10):e3219.
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). Accelerating work to overcome the global impact of neglected tropical diseases – a roadmap for implementastion. Geneva, Switzerland: WHO; 2012. Available from: http://www.who.int/entity/neglected_diseases/NTD_RoadMap_2012_Fullversion.pdf. Accessed April 22, 2015.
   Google Scholar
• Chagas Disease Coalition [homepage on the Internet]. Available from: http://blogs.plos.org/speakingofmedicine/2013/10/31/declaration-of-the-global-chagas-disease-coalition/. Accessed April 20, 2015.
   Google Scholar